Page Image

Chronic Lymphocytic Leukemia

The latest news, research, and perspectives in chronic lymphocytic leukemia (CLL). The most common leukemia subtype among adults, CLL occurs when an acquired mutation causes bone marrow to produce abnormal lymphocytes. As these leukemic cells proliferate, the disorder is associated with lymphadenopathy, splenomegaly, and cytopenias.

Advertisement
Advertisement
Paolo Ghia, MD, PhDChronic Lymphocytic Leukemia | April 9, 2024
Paolo Ghia, MD, PhD talks about his session on monoclonal B-cell lymphocytosis presented at the AACR Annual Meeting 2024.
View More
Elias Jabbour, MDChronic Lymphocytic Leukemia | March 29, 2024
Elias Jabbour, MD, discusses the latest news and novel therapies in CLL.
Melissa BadamoChronic Lymphocytic Leukemia | March 29, 2024
In patients with CLL, zanubrutinib showed advantages in PFS and CR rates with "potentially improved" OS.
Tanya Siddiqi, MDChronic Lymphocytic Leukemia | March 29, 2024
Dr. Siddiqi shares data from the phase I/II TRANSCEND CLL 004 trial on liso-cel in patients with relapsed or refractory CLL.
Patrick DalyChronic Lymphocytic Leukemia | March 19, 2024
Treatment with ibrutinib plus FCR followed by ibrutinib maintenance induced durable and deep responses in patients with CLL.
Melissa BadamoChronic Lymphocytic Leukemia | March 29, 2024
The CAR-T therapy was approved based on response rate and duration of response data from the TRANSCEND CLL 004 trial.
Melissa BadamoChronic Lymphocytic Leukemia | March 11, 2024
The researchers developed CAR T-cells that target and eliminate mutated CLL cells while sparing healthy B-cells.
Patrick DalyChronic Lymphocytic Leukemia | February 21, 2024
Acalabrutinib with or without obinutuzumab had sustained safety and efficacy in patients with CLL in six years of follow-up.
Patrick DalyChronic Lymphocytic Leukemia | February 21, 2024
NX-2127, a first-in-class therapy, induced BTK degradation and clinical responses in CLL resistant to BTK inhibitors.
Melissa BadamoChronic Lymphocytic Leukemia | February 22, 2024
MRD-directed ibrutinib plus venetoclax therapy improved PFS in patients with CLL.
Justin Taylor, MDChronic Lymphocytic Leukemia | February 14, 2024
The study defined mutations that develop resistance to BTK inhibitors and evaluated the BTK degrader NX-2127 in CLL.
Mariia Mikhaleva, MDChronic Lymphocytic Leukemia | January 26, 2024
The presence of two or more mutations are associated with high-risk cell features.
Chaitra Ujjani, MDChronic Lymphocytic Leukemia | January 22, 2024
Chaitra Ujjani, MD, discusses research on the incidence and management of COVID-19 infections in patients with CLL.
Melissa BadamoChronic Lymphocytic Leukemia | January 22, 2024
Some mutations are associated with shorter event-free survival in low-risk, early-stage CLL.
Melissa BadamoChronic Lymphocytic Leukemia | January 18, 2024
The updated analysis found that combining rituximab with ibrutinib did not provide additional treatment benefit.
Blood Cancers Today Staff WritersChronic Lymphocytic Leukemia | January 16, 2024
The therapy is currently under investigation in multiple clinical trials.
Melissa BadamoChronic Lymphocytic Leukemia | February 2, 2024
The label update includes progression-free survival results from the ALPINE phase III trial.
Leah SherwoodChronic Lymphocytic Leukemia | January 5, 2024
Lisocabtagene maraleucel is a CD19-directed CAR T-cell therapy with a 4-1BB co-stimulatory domain.
Advertisement
Section Editor

Advertisement
Latest News

April 16, 2024